A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a skin-applied gene therapy called B-VEC for people aged 2 months and older with a severe skin condition called DEB. The treatment aims to help their skin produce a missing protein, making it stronger and less prone to blisters. The study will last several years to check if the treatment is safe and well-tolerated.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Who Is on the Research Team?
David Chien, MD
Principal Investigator
Senior Vice President of Clinical Development
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive weekly topical B-VEC therapy for Dystrophic Epidermolysis Bullosa
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Beremagene Geperpavec (B-VEC)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Krystal Biotech, Inc.
Lead Sponsor